Verrica Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRCA research report →
Companywww.verrica.com
Verrica Pharmaceuticals Inc. , a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.
- CEO
- Jayson Rieger
- IPO
- 2018
- Employees
- 71
- HQ
- West Chester, PA, US
Price Chart
Valuation
- Market Cap
- $64.12M
- P/E
- -3.60
- P/S
- 1.73
- P/B
- 3.99
- EV/EBITDA
- -3.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.52%
- Op Margin
- -36.39%
- Net Margin
- -47.97%
- ROE
- -1136.50%
- ROIC
- -58.02%
Growth & Income
- Revenue
- $35.58M · 370.22%
- Net Income
- $-17,886,000 · 76.64%
- EPS
- $-1.68 · 88.63%
- Op Income
- $-11,939,000
- FCF YoY
- 71.08%
Performance & Tape
- 52W High
- $9.82
- 52W Low
- $3.28
- 50D MA
- $6.12
- 200D MA
- $5.91
- Beta
- 1.55
- Avg Volume
- 108.51K
Get TickerSpark's AI analysis on VRCA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 25, 25 | BKB Growth Investments, LLC | other | 224,719 |
| Nov 25, 25 | BKB Growth Investments, LLC | other | 0 |
| Nov 25, 25 | BKB Growth Investments, LLC | other | 687,690 |
| Nov 25, 25 | BKB Growth Investments, LLC | other | 224,719 |
| Dec 23, 25 | Kirby John J. | other | 10,000 |
| Dec 26, 25 | Caligan Partners LP | other | 0 |
| Nov 25, 25 | Caligan Partners LP | other | 4,126,239 |
| Nov 22, 24 | Caligan Partners LP | other | 421,346 |
| Nov 25, 25 | Caligan Partners LP | other | 1,031,559 |
| Dec 26, 25 | Frantzreb Charles | other | 0 |
Our VRCA Coverage
We haven't published any research on VRCA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VRCA Report →